Alternative Data for NovoCure
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 49 | Sign up | Sign up | Sign up |
| Sentiment | 58 | Sign up | Sign up | Sign up |
| Webpage traffic | 28,000 | Sign up | Sign up | Sign up |
| Employee Rating | 64 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 15 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,810 | Sign up | Sign up | Sign up |
| X Followers | 2,750 | Sign up | Sign up | Sign up |
| X Mentions | 49 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 45 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,489 | Sign up | Sign up | Sign up |
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma.
| Price | $12.01 |
| Target Price | Sign up |
| Volume | 1,345,370 |
| Market Cap | $1.45B |
| Year Range | $10.03 - $18.46 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Industry | Medical & Dental Instruments |
In the news
 |
NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity ApproachingFebruary 12 - SeekingAlpha |
 |
NovoCure Stock Surges After FDA Approves Optune PaxFebruary 11 - Benzinga |
NovoCure shares are trading higher after the company announced FDA approval for Optune Pax.February 11 - Benzinga |
|
HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $47February 11 - Benzinga |
|
 |
NovoCure (NVCR) Stock Is Trending Overnight — Here's What You Should KnowFebruary 11 - Benzinga |
NovoCure Says FDA Approves NovoCure's Optune Pax For Treatment Of Locally Advanced Pancreatic CancerFebruary 11 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 167M | 45M | 122M | -37M | -26M | -0.330 |
| Q2 '25 | 159M | 41M | 117M | -40M | -36M | -0.360 |
| Q1 '25 | 155M | 39M | 116M | -34M | -35M | -0.310 |
| Q4 '24 | 161M | 33M | 128M | -66M | -11M | -0.610 |
| Q3 '24 | 155M | 35M | 120M | -31M | -30M | -0.280 |
Insider Transactions View All
| Paravasthu Mukund filed to sell 72,832 shares at $13.8. March 5 '26 |
| Weinberg Uri filed to sell 267,190 shares at $13.3. March 5 '26 |
| Leonard Frank X filed to sell 493,793 shares at $13.3. March 5 '26 |
| Puri Michal Nath filed to sell 201,322 shares at $13.3. March 5 '26 |
| Leupin Nicolas filed to sell 102,979 shares at $13.3. March 5 '26 |
Similar companies
Read more about NovoCure (NVCR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - NovoCure
The Market Cap of NovoCure is $1.45B.
Currently, the price of one share of NovoCure stock is $12.01.
The NVCR stock price chart above provides a comprehensive visual representation of NovoCure's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NovoCure shares. Our platform offers an up-to-date NVCR stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, NovoCure (NVCR) does not offer dividends to its shareholders. Investors interested in NovoCure should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of NovoCure are Align Technology, Dentsply, LeMaitre Vascular, iRhythm Technologies, and Danaher.
